Clinical Trial Update: Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immune response of an adjuvanted H5N1 inactivated, split-virion influenza vaccine in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus Infection
• Pandemic Influenza

Drugs mentioned

• Sanofi Pasteur H5N1 adjuvanted influenza vaccine (Influenza A(H5N1) vaccine, adjuvanted, inactivated, split-virus)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Pandemic Influenza, Influenza A Virus Infection | Phase 1 | Status: COMPLETED